What is the most appropriate next clinical trial for a man with metastatic castration‑resistant prostate cancer who has progressed after standard androgen‑receptor signaling inhibitor therapy (and, if applicable, taxane chemotherapy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Next Best Clinical Trial for mCRPC After ARPI Progression

For a man with metastatic castration-resistant prostate cancer who has progressed after androgen-receptor signaling inhibitor therapy, the most appropriate next clinical trial should evaluate 177Lu-PSMA-617 radiopharmaceutical therapy versus cabazitaxel chemotherapy in PSMA-positive patients, or investigate novel combination strategies that address taxane resistance mechanisms.

Primary Recommendation Based on Current Evidence Gaps

The 2025 ASCO guideline 1 identifies a critical knowledge gap: while 177Lu-PSMA-617 shows radiographic progression-free survival benefit in the post-ARPI, post-chemotherapy setting, and emerging data from PSMAfore and SPLASH trials demonstrate efficacy before chemotherapy, there is no head-to-head comparison between 177Lu-PSMA-617 and cabazitaxel in the immediate post-ARPI setting 1. This represents the most clinically relevant unanswered question.

Key Trial Design Elements:

Primary endpoint: Overall survival (not just radiographic PFS), as both PSMAfore and SPLASH failed to show OS benefit, likely due to crossover 1

Population stratification:

  • PSMA-positive imaging (mandatory)
  • Prior ARPI exposure (abiraterone or enzalutamide)
  • Stratify by prior docetaxel in hormone-sensitive setting
  • Stratify by disease volume and symptom burden

Control arm: Cabazitaxel (not ARPI switching), as CARD trial established cabazitaxel superiority over second ARPI with OS benefit (13.6 vs 11.0 months, HR 0.64) 1

Alternative High-Priority Trial Designs

1. Biomarker-Directed Combination Strategies

The 2026 literature emphasizes that taxane resistance is biologically heterogeneous and incompletely captured by current biomarkers 2. A trial should:

  • Evaluate cabazitaxel combined with targeted agents addressing specific resistance mechanisms (PI3K/AKT/mTOR inhibitors, AR degraders)
  • Include mandatory tumor biopsies at progression to identify resistance pathways
  • Use adaptive design allowing biomarker-selected cohort expansion

2. Triplet Intensification in Earlier Disease States

Given the shift toward early treatment intensification 3, a critical gap exists in understanding optimal sequencing after progression on ADT + ARPI ± docetaxel triplet therapy. Trial should:

  • Enroll patients who progressed specifically after triplet therapy (increasingly common scenario)
  • Compare novel mechanisms (PARP inhibitors in HRR-mutated, bispecific T-cell engagers) versus standard cabazitaxel
  • Include quality of life as co-primary endpoint given cumulative toxicity concerns

Critical Design Considerations

Avoid Common Pitfalls from Recent Trials:

Crossover contamination: PSMAfore and SPLASH both had ~51% crossover rates, obscuring OS benefit 1. Design must either prohibit crossover or use rank-preserving structural failure time models for analysis.

Inadequate control arms: Many recent trials used ARPI switching as control despite known inferior efficacy 1, 4. Use mechanism-based active comparators.

Selection bias: Trials increasingly enroll highly selected patients, limiting generalizability 5. Include broader eligibility:

  • Age >75 years
  • ECOG performance status 2
  • Moderate renal/hepatic impairment
  • Prior radiation to >25% bone marrow

Mandatory Correlative Studies:

Per PCWG3 guidelines 6, trials must include:

  • Circulating tumor DNA analysis for AR variants and resistance mutations
  • Serial PSMA PET imaging (not just at baseline)
  • Patient-reported outcomes using validated instruments
  • Bone scan progression documented per 2+2 rule with confirmation scans

Emerging Mechanisms Warranting Investigation

The 2026 evidence highlights several investigational approaches 2, 7:

Highest priority combinations:

  • Cabazitaxel + PARP inhibitor (in HRR-mutated subset)
  • Cabazitaxel + platinum (exploiting DNA damage synergy)
  • AR degraders (avoiding cross-resistance with prior ARPIs)
  • Bispecific T-cell engagers targeting PSMA or other prostate antigens

Lower priority (based on systematic review showing minimal benefit 4):

  • Checkpoint inhibitor monotherapy (reserve for MSI-H/dMMR only per guideline 1)
  • Sequential ARPI therapy (established inferior to cabazitaxel)

Trial Endpoints Aligned with Clinical Outcomes

Following PCWG3 recommendations 6, structure endpoints by disease manifestation:

Primary: Overall survival (mandatory for registration)

Key secondary:

  • Radiographic PFS per RECIST 1.1 (nodes/visceral) and bone scan (2+2 rule with confirmation)
  • PSA response (≥50% decline from baseline)
  • Time to symptomatic progression
  • Quality of life (FACT-P or similar)

Exploratory:

  • Circulating tumor cell counts
  • Pain progression (Brief Pain Inventory)
  • Time to first skeletal-related event

Population-Specific Considerations

For post-ARPI, pre-chemotherapy patients: 177Lu-PSMA-617 vs cabazitaxel is the most urgent comparison

For post-ARPI, post-docetaxel patients: Novel mechanisms (AR degraders, bispecifics) vs cabazitaxel or 177Lu-PSMA-617

For HRR-mutated patients: PARP inhibitor combinations vs monotherapy (addressing the PROpel finding of benefit with abiraterone + olaparib in BRCA1/2/ATM mutations 1)

The trial design must acknowledge that real-world treatment patterns show continued second-line ARPI use despite inferior efficacy 1, driven by patient preference and toxicity concerns—making quality of life endpoints particularly critical for changing practice patterns.

Related Questions

What is the appropriate third-line treatment for a patient with stage IV (metastatic) castration‑resistant prostate cancer and an ATR (ataxia‑telangiectasia and Rad3‑related) mutation after prior androgen‑deprivation therapy, an androgen‑receptor‑targeted agent, and taxane chemotherapy?
Can docetaxel be administered together with androgen deprivation therapy and enzalutamide in castration‑resistant prostate cancer?
What is the recommended dosing, administration, monitoring, and contraindications for Gemtesa (darolutamide) in patients with metastatic castration‑resistant prostate cancer receiving androgen‑deprivation therapy?
How should cardiac toxicity be managed in a patient with metastatic castration‑resistant prostate cancer receiving abiraterone (Zytiga) 1 g daily and prednisone 5 mg twice daily?
What is the recommended dosing, monitoring, and contraindications for abiraterone acetate in a patient with metastatic castration‑resistant prostate cancer receiving continuous androgen‑deprivation therapy?
What is the recommended anticoagulant prophylaxis management, including drug selection, dosing, and duration, for an adult patient at risk for venous thromboembolism?
What is the differential diagnosis and appropriate workup for sticky, gluey, mustard‑yellow stools with occasional dark, cherry‑wood‑colored stools?
What are the symptoms and recommended treatments for cluster headaches?
In a patient taking oral terbinafine 250 mg daily for onychomycosis who is also on a statin, does terbinafine affect cholesterol levels or require special monitoring?
Do vincristine, methotrexate, or ondansetron cause vasodilation?
When should Flublok (recombinant hemagglutinin influenza vaccine) be used instead of a standard quadrivalent inactivated influenza vaccine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.